Skip to main content
Skip to main content
ALBHF logo

Alibaba Health Information Technology Limited (ALBHF)

$0.42 +$0.01 (+2.44%) |CouncilHOLD · 45 · C
Bottom line: HOLD — our Council read (45/100) and AI Score (45/100) broadly agree.
MCap: $6.77B| P/E Ratio: 20.1| Vol: 100| 52-wk range: $0.47 – $0.90
Data from FMP · Methodology

For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

Alibaba Health Information Technology Limited (ALBHF) trades at $0.42 with AI Score 45/100 (Grade C). Alibaba Health Information Technology Limited operates a comprehensive digital healthcare platform in Mainland China and Hong Kong, focusing on pharmaceutical direct sales, e-commerce, and various healthcare and digital services. Market cap: $6.77B, Sector: Healthcare.

Price live · AI analysis from Jun 15, 2026
Alibaba Health Information Technology Limited operates a comprehensive digital healthcare platform in Mainland China and Hong Kong, focusing on pharmaceutical direct sales, e-commerce, and various healthcare and digital services. The company leverages its integration within the broader Alibaba ecosystem to connect patients, pharmacies, and healthcare providers.

Analyst Coverage for ALBHF: ALBHF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ALBHF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.

Council Score · Weighted Average of 3 Disciplines
HOLD 45/100 · C

ALBHF: the 1 perspectives are evenly split.

How is this calculated? →
Council Score · 8 perspectives · See tabs for details →

Alibaba Health Information Technology Limited (ALBHF) Healthcare & Pipeline Overview

CEODifan Shen
Employees1422
HeadquartersCauseway Bay, HK
IPO Year2018

Alibaba Health Information Technology Limited is a Hong Kong-based investment holding company driving digital healthcare in Mainland China, specializing in pharmaceutical e-commerce, direct sales, and a wide array of online medical and wellness services. It leverages the extensive Alibaba ecosystem to provide integrated health solutions to B2C and B2B customers.

Data Provenance | Financial Data Quantitative Analysis NASDAQ Analysis: Jun 15, 2026

What Is the Investment Thesis for ALBHF?

Alibaba Health Information Technology Limited operates as a key digital healthcare enabler in China, capitalizing on the expansive growth of online pharmaceutical sales and digital health services. With a market capitalization of $6.77B, the company exhibits a P/E ratio of 20.1, reflecting investor confidence in its growth trajectory. Its operational efficiency is highlighted by a 5.1% profit margin and a 23.9% gross margin. A primary growth catalyst is its deep integration within the Alibaba ecosystem, providing unparalleled access to a vast user base across platforms like Taobao, Tmall, and Alipay, which fuels its pharmaceutical e-commerce and digital service adoption. The company's comprehensive service offerings, from direct drug sales to medical consultations and vaccinations, position it to capture increasing demand for convenient healthcare solutions. However, investors must closely monitor the ongoing regulatory landscape in the Chinese technology sector, as evolving policies could introduce operational challenges. The company's beta of 1.72 suggests higher market volatility, a factor to consider in risk assessment.

Based on FMP financials and quantitative analysis

ALBHF Key Highlights

  • Alibaba Health Information Technology Limited commands a market capitalization of $6.77B, reflecting its significant presence in the digital healthcare market.
  • The company maintains a P/E ratio of 20.1, indicating investor expectations for future earnings growth relative to its current share price.
  • A profit margin of 5.1% demonstrates the company's ability to convert revenue into net income amidst its extensive operational scale.
  • Alibaba Health achieves a gross margin of 23.9%, showcasing its profitability at the core business level before operating expenses.
  • The company's Beta of 1.72 suggests higher volatility compared to the broader market, indicating a more sensitive response to market fluctuations.

Who Are ALBHF's Competitors?

ALBHF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

Company Price Change Market Cap AI Score
SSSGY Sartorius AG $43.93 +0.00% $15.17B 51
SGIOY Shionogi & Co., Ltd. $8.97 +3.70% $15.27B 61
SONVY Sonova Holding AG $51.65 +2.57% $15.34B 50
FSPKF Fisher & Paykel Healthcare Corporation Limited $22.52 +0.00% $13.23B 51
OCPNF Olympus Corporation $10.01 +0.00% $11.02B 50
ATAI Atai Beckley NV is a clinical-stage biopharmaceutical company focused on developing treatments for mental health disorders. The company $4.88 -5.97% $1.80B 68
MEDS TRxADE HEALTH, Inc. $7.59 +4.55% $13.28M 63
ONC BeOne Medicines Ltd. $309.46 +3.97% $33.07B 61

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are ALBHF's Key Strengths?

  • Strong affiliation with the Alibaba ecosystem provides extensive user access and technological support.
  • Comprehensive service offering covering pharmaceutical direct sales, e-commerce, and diverse digital healthcare services.
  • Established market presence in Mainland China and Hong Kong's rapidly growing digital health sector.
  • Robust multi-channel distribution and service delivery network through major digital platforms.

What Are ALBHF's Weaknesses?

  • Exposure to significant regulatory risks within the Chinese technology and healthcare sectors.
  • Reliance on the broader Alibaba ecosystem for platform integration and user base.
  • Trading on the OTC Other tier, which may imply lower liquidity and transparency.
  • Potential for intense competition from other e-commerce giants and specialized health tech companies.

What Could Drive ALBHF Stock Higher?

  • Continued expansion of its pharmaceutical e-commerce platform and direct sales network, driven by increasing digital adoption in healthcare across China.
  • Further integration and leveraging of the Alibaba ecosystem (Taobao, Tmall, Alipay) to enhance user acquisition and service accessibility for healthcare offerings.
  • Potential introduction of new digital healthcare services or expansion into additional therapeutic areas to meet evolving consumer demands.
  • Strategic partnerships or collaborations aimed at enhancing its internet hospital capabilities and telemedicine infrastructure.
  • Regulatory clarity or supportive policies from Chinese authorities regarding online healthcare and data management, potentially reducing operational uncertainties.

What Are the Key Risks for ALBHF?

  • Regulatory risks within the Chinese technology and healthcare sectors, which could lead to new compliance requirements or operational restrictions.
  • Intense competition from other established e-commerce platforms and emerging digital health startups in China.
  • Dependence on the broader Alibaba ecosystem, meaning any adverse developments affecting Alibaba Group could indirectly impact ALBHF.
  • Operational challenges and lower liquidity associated with trading on the OTC Other tier, affecting investor confidence and trading efficiency.
  • Economic slowdowns in Mainland China or changes in consumer spending habits on healthcare products and services.

What Are the Growth Opportunities for ALBHF?

  • Growth opportunity 1: Expansion of its Pharmaceutical E-commerce Platform. Alibaba Health's e-commerce platform, offering a wide array of pharmaceutical products, medical devices, and health foods, is poised for significant growth. The increasing consumer preference for online purchasing, particularly for health-related items, coupled with China's vast population, presents a substantial market opportunity. By enhancing logistics, expanding product categories, and integrating AI-driven personalized recommendations, the company can capture a larger share of the estimated multi-trillion-dollar global e-pharmacy market, with China being a primary driver. This expansion timeline is ongoing, driven by continuous platform development and user acquisition strategies.
  • Growth opportunity 2: Diversification and Scaling of Healthcare and Digital Services. The company's portfolio of medical and healthcare services, including checkups, nucleic acid testing, consultations, and vaccinations, represents a strong growth avenue. As digital health literacy improves and demand for convenient, accessible healthcare rises, Alibaba Health can scale these services by expanding its network of providers and leveraging telemedicine technologies. The market for digital health services in China is projected to grow substantially, offering a long-term opportunity for the company to deepen its engagement with users and generate recurring revenue streams through subscription models or service fees.
  • Growth opportunity 3: Leveraging the Alibaba Ecosystem for User Acquisition and Engagement. Alibaba Health's deep integration with platforms like Taobao, Tmall, Alipay, and DingTalk provides a unique competitive advantage for user acquisition and retention. This ecosystem allows for cross-promotion, seamless payment integration, and access to a massive existing user base, significantly reducing customer acquisition costs. Further optimizing these synergies, such as personalized health recommendations based on user shopping habits or integrating health services directly into daily-use apps, can unlock substantial growth. This ongoing strategy reinforces its market position and expands its reach across diverse demographics.
  • Growth opportunity 4: Development and Operation of Internet Hospitals. The operation of internet hospitals is a critical growth driver, aligning with China's push for digital transformation in healthcare. These platforms enable remote consultations, prescription services, and chronic disease management, addressing geographical disparities in healthcare access. By investing in advanced telemedicine infrastructure, recruiting more medical professionals, and expanding specialized departments, Alibaba Health can tap into the vast underserved rural and urban populations. This represents a multi-year growth opportunity, with increasing regulatory support for online medical services driving market adoption and expansion.
  • Growth opportunity 5: Expansion into Business-to-Business (B2B) Pharmaceutical Solutions. While serving B2C customers, Alibaba Health also engages in B2B pharmaceutical sales. There is significant potential to expand this segment by offering comprehensive supply chain solutions, bulk purchasing platforms, and digital tools for pharmacies and healthcare institutions. Streamlining procurement processes, improving inventory management, and providing data analytics to B2B clients can create substantial value. This growth opportunity, while requiring robust logistics and strong supplier relationships, can unlock a large market segment and diversify revenue streams over the medium to long term.
  • Growth opportunity 6: Data-Driven Health Management and Personalized Services. Leveraging the vast amount of health data collected through its platforms, Alibaba Health has an opportunity to develop advanced data-driven health management and personalized services. This includes AI-powered diagnostic support, predictive health analytics, and customized wellness programs. By offering tailored health advice, preventive care recommendations, and precision medicine insights, the company can enhance user engagement and create new revenue streams through premium services or partnerships with insurance providers. This long-term opportunity positions Alibaba Health at the forefront of innovative digital health solutions.

What Opportunities Does ALBHF Have?

  • Continued expansion of digital healthcare adoption and e-pharmacy market in China.
  • Development of new specialized healthcare services and integration of AI/data analytics.
  • Growth in B2B pharmaceutical supply chain solutions and partnerships.
  • Increased demand for remote medical consultations and internet hospital services.

What Threats Does ALBHF Face?

  • Evolving and potentially stricter government regulations impacting online healthcare and data privacy.
  • Intensifying competition from domestic and international players entering the digital health market.
  • Economic slowdowns or changes in consumer spending habits in China.
  • Cybersecurity risks and data breaches inherent in large-scale digital platforms.

What Are ALBHF's Competitive Advantages?

  • Deep integration and strong affiliation with the extensive Alibaba ecosystem, providing access to a massive user base and robust technological infrastructure.
  • Comprehensive digital healthcare platform offering a wide array of services from pharmaceutical e-commerce to online medical consultations and vaccinations.
  • Significant market presence and brand recognition in Mainland China and Hong Kong's digital health sector.
  • Multi-channel access points for users through popular Alibaba platforms like Taobao, Tmall, Alipay, and dedicated apps.
  • Established supply chain and logistics capabilities for pharmaceutical direct sales and distribution.

What Does ALBHF Do?

Alibaba Health Information Technology Limited, an investment holding company headquartered in Causeway Bay, Hong Kong, is a prominent player in the digital healthcare sector across Mainland China and Hong Kong. The company was originally established as CITIC 21CN Company Limited before undergoing a significant transformation and rebranding to Alibaba Health Information Technology Limited in September 2014, aligning itself with the vast Alibaba ecosystem. Its core business operations are segmented into three primary areas: pharmaceutical direct sales, a comprehensive pharmaceutical e-commerce platform, and a diverse portfolio of healthcare and digital services. Through its online storefronts on Tmall.com and a network of offline pharmacy outlets, Alibaba Health facilitates the direct sale of a broad spectrum of health-related products. This includes prescription drugs, over-the-counter medications, nutritional supplements, various medical devices, contact lenses, and other health commodities, serving both business-to-customer (B2C) and business-to-business (B2B) segments. Concurrently, its robust e-commerce platform extends beyond direct sales, offering a marketplace for pharmaceutical products, medical devices, healthcare products, health food, sexual health and family planning items, and contact lenses, alongside facilitating access to medical and healthcare services. Beyond product sales, Alibaba Health is deeply invested in providing a wide array of medical and healthcare services. These include essential offerings such as medical checkups, nucleic acid testing, medical consultations, appointment registration, vaccination services, and traditional Chinese medicine (TCM) consultations. These services are made accessible through a multi-channel approach, leveraging popular platforms within the Alibaba ecosystem like Taobao, Tmall, Alipay, as well as its proprietary Dr. Deer APP, Gaode, DingTalk, and Quark. The company also engages in specialized activities such as tracking businesses, providing network hospital and healthcare-related internet information services, operating internet hospitals, and offering asset management services, solidifying its position as an integrated digital health solutions provider.

What Products and Services Does ALBHF Offer?

  • Operates a pharmaceutical direct sales business through online stores on Tmall.com and offline pharmacy outlets.
  • Manages a comprehensive e-commerce platform for pharmaceutical products, medical devices, health food, and other health-related items.
  • Provides a wide range of medical and healthcare services, including checkups, nucleic acid testing, medical consultations, and vaccinations.
  • Offers Traditional Chinese Medicine (TCM) services through various digital channels.
  • Engages in the tracking business, providing solutions for product traceability.
  • Delivers network hospital, healthcare-related internet information, and technical services.
  • Operates internet hospitals, facilitating online medical consultations and services.
  • Provides asset management services within the healthcare sector.

How Does ALBHF Make Money?

  • Generates revenue from direct sales of pharmaceutical and health products to B2C and B2B customers.
  • Earns commissions and service fees from its e-commerce platform for transactions involving third-party sellers and service providers.
  • Derives income from providing various medical and digital healthcare services, such as consultations, testing, and vaccinations.
  • Monetizes its tracking business and provision of technical and internet information services to healthcare entities.
  • Engages in asset management services, contributing to its investment holding company structure.

What Industry Does ALBHF Operate In?

Alibaba Health Information Technology Limited operates within the dynamic and rapidly expanding digital healthcare and medical pharmaceuticals industry in Mainland China and Hong Kong. This sector is characterized by a significant shift towards online platforms for drug sales, medical consultations, and health management, driven by increasing internet penetration, smartphone adoption, and government initiatives promoting 'Internet+ Healthcare.' The competitive landscape includes traditional pharmacy chains, other e-commerce giants expanding into healthcare, and specialized digital health startups. Alibaba Health distinguishes itself through its comprehensive ecosystem approach, leveraging the vast user base and technological infrastructure of the Alibaba group. This integration provides a unique competitive advantage in customer acquisition and service delivery, positioning it as a leading platform connecting consumers, pharmacies, and healthcare providers in a fragmented yet high-growth market.

Who Are ALBHF's Key Customers?

  • Individual consumers (B2C) seeking prescription drugs, OTC medications, nutritional supplements, and various health services.
  • Businesses (B2B) including pharmacies and healthcare institutions purchasing pharmaceutical products and medical devices.
  • Patients utilizing online medical consultation, registration, and vaccination services.
  • Users of the Alibaba ecosystem platforms (Taobao, Tmall, Alipay) seeking health-related products and services.
  • Healthcare providers and institutions leveraging its network hospital and technical services.
AI Confidence: 83% Updated: Jun 15, 2026

Alibaba Health Information Technology Limited (ALBHF) Valuation Context

Valued at $6.77B, ALBHF is classified as a mid-cap stock. Relative to its peer group, ALBHF's quantitative score of 45/100 is roughly in line with the peer average of 53/100.

ALBHF Revenue & Earnings Trend

In Q1 2026, ALBHF generated $17.14B in top-line revenue, marking a sequential increase of 3.4%. The company recorded net income of $653.6M, with diluted EPS of $0.04. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this mid-cap Healthcare company. Across the four most recent quarters, ALBHF averaged $0.04 in diluted EPS.

Company Profile

Alibaba Health Information Technology Limited operates in the Medical - Pharmaceuticals industry within the Healthcare sector. It is headquartered in Causeway Bay, HK. The company is led by CEO Difan Shen. ALBHF has traded publicly since 2018.

ROE 15%Key Financial Metrics

Return on equity for Alibaba Health Information Technology Limited stands at 15.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 11.3%, showing how much profit it generates from its asset base. ALBHF trades at a trailing price-to-earnings ratio of 20.08, below the Healthcare sector average of ~23x. Its free cash flow yield is 3.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.03 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 5.0%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 5/9Financial Health

Alibaba Health Information Technology Limited's Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 8.68 places it in the safe zone, indicating low near-term bankruptcy risk.

FY2026 estForward Outlook

Wall Street analysts project Alibaba Health Information Technology Limited revenue of about $35.01B for fiscal 2026, with EPS near $0.14. The estimate reflects 16 contributing analysts.

ALBHF Financials

Fundamental Snapshot

Revenue Growth (FY)
+8.0%
Net Income Growth (FY)
+30.3%
EPS Growth (FY)
+34.7%
P/E (TTM)
20.1
Return on Equity (TTM)
+15.3%
Current Ratio
3.0
EV/EBITDA (TTM)
21.6

Based on FMP financials and quantitative analysis · FY 2026

Bull Case vs Bear Case

Bull Case

  • Strong affiliation with the Alibaba ecosystem provides extensive user access and technological support.
  • Comprehensive service offering covering pharmaceutical direct sales, e-commerce, and diverse digital healthcare services.
  • Established market presence in Mainland China and Hong Kong's rapidly growing digital health sector.
  • Robust multi-channel distribution and service delivery network through major digital platforms.

Bear Case

  • Exposure to significant regulatory risks within the Chinese technology and healthcare sectors.
  • Reliance on the broader Alibaba ecosystem for platform integration and user base.
  • Trading on the OTC Other tier, which may imply lower liquidity and transparency.
  • Potential for intense competition from other e-commerce giants and specialized health tech companies.

AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026

Recent Quarterly Results

Quarter Revenue Net Income EPS
Q1 2026 $17.14B $654M $0.04
Q3 2025 $16.58B $1.26B $0.08
Q1 2025 $16.32B $663M $0.04
Q4 2024 $8.16B $332M $0.02

Based on FMP financials and quantitative analysis

ALBHF Latest News

No recent news available for ALBHF.

ALBHF Analyst Consensus

Consensus Rating

Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ALBHF.

Price Targets

Wall Street price target analysis for ALBHF.

ALBHF MoonshotScore

45/100

What does this score mean?

The MoonshotScore rates ALBHF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.

Leadership: Difan Shen

Unknown

Unknown. Information regarding Difan Shen's specific career history, educational background, and previous roles prior to managing Alibaba Health Information Technology Limited is not provided in the available source data. His professional credentials and experience leading large organizations are not detailed.

Track Record: Unknown. Key achievements, strategic decisions, or company milestones directly attributable to Difan Shen's leadership at Alibaba Health Information Technology Limited are not specified in the provided information. The impact of his tenure on the company's growth, market position, or operational efficiency is not detailed.

ALBHF OTC Market Information

Alibaba Health Information Technology Limited trades on the OTC Other tier, which is the lowest of the three tiers on the OTC Markets Group's quotation system. Unlike companies listed on major exchanges like the NYSE or NASDAQ, which adhere to stringent listing requirements for financial reporting, corporate governance, and minimum share prices, companies on the OTC Other tier have minimal to no public disclosure requirements. This tier typically includes companies that do not provide current information to the public, or those that are in financial distress. It differs significantly from OTCQX and OTCQB, which require higher levels of financial reporting and transparency, making it a segment with the least regulatory oversight.

  • OTC Tier: OTC Other
  • Disclosure Status: Unknown
Liquidity: Trading on the OTC Other tier generally implies significantly lower liquidity compared to stocks on major exchanges. Investors in ALBHF may encounter wider bid-ask spreads, which can result in higher transaction costs and difficulty in executing trades at desired prices. The volume of shares traded can be inconsistent and often low, potentially leading to increased price volatility and challenges in efficiently entering or exiting positions. This reduced liquidity can also make it harder to find buyers or sellers, impacting the overall market efficiency for the stock.
OTC Risk Factors:
  • Limited public disclosure and financial transparency, making comprehensive due diligence challenging for investors.
  • Significantly lower liquidity compared to major exchanges, leading to wider bid-ask spreads and potential difficulty in trading.
  • Increased volatility and potential for price manipulation due to fewer market participants and reduced regulatory oversight.
  • Difficulty in obtaining reliable and timely information for informed investment decisions.
  • Higher risk of investment loss due to the less regulated and more opaque nature of the OTC Other market.
Due Diligence Checklist:
  • Verify any available financial statements and reports, even if limited, from official sources.
  • Research the company's business operations, market position, and competitive landscape thoroughly.
  • Assess the management team's background, experience, and any public statements.
  • Understand the specific regulatory environment in which the company operates, particularly in China's healthcare sector.
  • Evaluate the potential impact of limited liquidity and wider bid-ask spreads on investment strategy.
  • Scrutinize any news or press releases for signs of legitimacy or potential red flags.
  • Consult with a financial advisor who has experience with OTC market investments.
Legitimacy Signals:
  • Affiliation with the broader Alibaba ecosystem, a globally recognized and established technology conglomerate.
  • Headquartered in Causeway Bay, Hong Kong, a major international financial and business hub.
  • Engages in established and growing business models within pharmaceutical e-commerce and digital healthcare services.
  • Employs a substantial workforce of 1422 individuals, indicating a significant operational scale.
  • Operates in a regulated industry (healthcare) within China and Hong Kong, suggesting a degree of oversight.

Alibaba Health Information Technology Limited Healthcare Stock: Key Questions Answered

What does Alibaba Health Information Technology Limited do?

Alibaba Health Information Technology Limited is an investment holding company based in Hong Kong, primarily operating in Mainland China. It focuses on three core areas: pharmaceutical direct sales, a comprehensive pharmaceutical e-commerce platform, and a range of healthcare and digital services. The company sells prescription and over-the-counter drugs, nutritional supplements, and medical devices through Tmall.com and offline pharmacies. Its platform also facilitates medical checkups, nucleic acid testing, online consultations, vaccinations, and Traditional Chinese Medicine services, utilizing popular Alibaba platforms like Taobao, Tmall, and Alipay to reach a broad customer base. Additionally, it engages in tracking services, network hospital operations, and healthcare-related technical services.

What are the key growth opportunities for ALBHF in healthcare?

Alibaba Health Information Technology Limited has several key growth opportunities within the healthcare sector. The ongoing digitalization of healthcare in China presents a significant opportunity for its pharmaceutical e-commerce platform to expand its market share by offering a wider range of products and enhancing logistics. Furthermore, the company can scale its digital healthcare services, such as online consultations, medical checkups, and vaccinations, to meet increasing demand for convenient and accessible care. Leveraging its deep integration with the Alibaba ecosystem allows for unparalleled user acquisition and engagement, driving adoption of its health services. The development and expansion of its internet hospitals also represent a substantial long-term growth driver, addressing healthcare access disparities and enabling remote patient management.

What are the main risks for ALBHF?

Alibaba Health Information Technology Limited faces several significant risks. A primary concern is the ongoing regulatory environment in the Chinese technology and healthcare sectors, where evolving policies could impose new restrictions on data usage, platform operations, or pricing strategies. The company also faces intense competition from other large e-commerce players and specialized digital health startups vying for market share in China's rapidly growing online healthcare space. Its strong reliance on the broader Alibaba ecosystem means that any adverse developments affecting the parent company could indirectly impact ALBHF. Furthermore, as an OTC Other tier stock, it is subject to risks associated with lower liquidity, reduced transparency, and potential volatility, which can affect investor confidence and trading efficiency.

How does Alibaba Health Information Technology Limited leverage its affiliation with the Alibaba ecosystem?

Alibaba Health Information Technology Limited significantly leverages its affiliation with the broader Alibaba ecosystem to drive its business operations and market reach. This integration provides unparalleled access to a vast user base across popular platforms such as Taobao, Tmall, and Alipay, facilitating extensive customer acquisition for its pharmaceutical e-commerce and direct sales. The ecosystem enables seamless payment processing, robust technological infrastructure, and cross-promotional opportunities. Furthermore, its digital healthcare services, including medical consultations and vaccinations, are accessible through these widely used platforms, as well as specialized apps like Dr. Deer APP, Gaode, DingTalk, and Quark, ensuring high visibility and convenience for users. This deep integration is a core competitive advantage, enhancing operational efficiency and market penetration.

What are the implications of ALBHF trading on the OTC market?

Alibaba Health Information Technology Limited trading on the OTC Other tier carries several implications for investors. This tier signifies minimal public disclosure requirements, which can lead to limited financial transparency and make comprehensive due diligence challenging. Investors may experience significantly lower liquidity compared to stocks on major exchanges, resulting in wider bid-ask spreads and potential difficulties in executing trades at desired prices. The stock may also be subject to higher volatility due to fewer market participants and less regulatory oversight. While its affiliation with Alibaba Group provides some legitimacy, the OTC listing itself means investors must exercise increased caution and be prepared for potential challenges related to information access and trading efficiency.

What are the key factors to evaluate for ALBHF?

Alibaba Health Information Technology Limited (ALBHF) holds an AI score of 45/100 (low). P/E: 20.1x vs the S&P 500's ~20-25x. Not financial advice.

How frequently does ALBHF data refresh on this page?

ALBHF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.

What has driven ALBHF's recent stock price performance?

Alibaba Health Information Technology Limited (ALBHF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Strong affiliation with the Alibaba ecosystem provides extensive user access and technological support. See the News tab for the latest drivers. Past performance does not predict future results.

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources

Price as of Analysis updated AI Score refreshed daily
Data Sources & Methodology
Market data powered by Financial Modeling Prep & Yahoo Finance. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.
Data provided as-is for educational purposes. Not financial advice. Methodology

Data provided for informational purposes only.

Analysis Notes
  • All information is derived solely from the provided source data. No external information or speculation was used.
Data Sources

Popular Stocks